CA2504938C - Compositions and methods for treating or preventing pneumococcal infection - Google Patents

Compositions and methods for treating or preventing pneumococcal infection Download PDF

Info

Publication number
CA2504938C
CA2504938C CA2504938A CA2504938A CA2504938C CA 2504938 C CA2504938 C CA 2504938C CA 2504938 A CA2504938 A CA 2504938A CA 2504938 A CA2504938 A CA 2504938A CA 2504938 C CA2504938 C CA 2504938C
Authority
CA
Canada
Prior art keywords
seq
polypeptide
composition
immune response
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA2504938A
Other languages
English (en)
French (fr)
Other versions
CA2504938A1 (en
Inventor
Michael C. Chen
Chuang-Jiun Chiou
Zhongming Li
Dong-Sheng Chen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Synergy America Inc
Original Assignee
Synergy America Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synergy America Inc filed Critical Synergy America Inc
Publication of CA2504938A1 publication Critical patent/CA2504938A1/en
Application granted granted Critical
Publication of CA2504938C publication Critical patent/CA2504938C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1271—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Micrococcaceae (F), e.g. Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • C07K14/3156—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci from Streptococcus pneumoniae (Pneumococcus)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6087—Polysaccharides; Lipopolysaccharides [LPS]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CA2504938A 2002-11-07 2003-11-06 Compositions and methods for treating or preventing pneumococcal infection Expired - Lifetime CA2504938C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US42449702P 2002-11-07 2002-11-07
US60/424,497 2002-11-07
PCT/US2003/035529 WO2004043376A2 (en) 2002-11-07 2003-11-06 Compositions and methods for treating or preventing pneumococcal infection

Publications (2)

Publication Number Publication Date
CA2504938A1 CA2504938A1 (en) 2004-05-27
CA2504938C true CA2504938C (en) 2011-10-11

Family

ID=32312819

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2504938A Expired - Lifetime CA2504938C (en) 2002-11-07 2003-11-06 Compositions and methods for treating or preventing pneumococcal infection

Country Status (10)

Country Link
US (2) US7217791B2 (cg-RX-API-DMAC7.html)
EP (1) EP1558280B1 (cg-RX-API-DMAC7.html)
JP (3) JP2006506989A (cg-RX-API-DMAC7.html)
KR (1) KR20050086427A (cg-RX-API-DMAC7.html)
CN (1) CN100443116C (cg-RX-API-DMAC7.html)
AU (1) AU2003291365B2 (cg-RX-API-DMAC7.html)
CA (1) CA2504938C (cg-RX-API-DMAC7.html)
ES (1) ES2451620T3 (cg-RX-API-DMAC7.html)
TW (1) TWI315986B (cg-RX-API-DMAC7.html)
WO (1) WO2004043376A2 (cg-RX-API-DMAC7.html)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8128939B2 (en) 2007-04-13 2012-03-06 The Board Of Regents Of The University Of Oklahoma Mutants of cholesterol-dependent cytolysins and uses thereof
GB0714963D0 (en) 2007-08-01 2007-09-12 Novartis Ag Compositions comprising antigens
AU2009208403A1 (en) 2008-02-01 2009-08-06 Newcastle Innovation Limited Vaccine compositions
AU2010227220B2 (en) 2009-03-24 2014-11-13 Glaxosmithkline Biologicals S.A. Combinations of meningococcal factor H binding protein and pneumococcal saccharide conjugates
SG178904A1 (en) 2009-09-10 2012-04-27 Novartis Ag Combination vaccines against respiratory tract diseases
GB201003922D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Conjugation process
EP2550289A4 (en) 2010-03-12 2013-11-27 Childrens Medical Center NEW IMMUNOGENES AND METHODS FOR IDENTIFICATION AND SCREENING THEREOF
WO2012072769A1 (en) 2010-12-01 2012-06-07 Novartis Ag Pneumococcal rrgb epitopes and clade combinations
CN108578685A (zh) * 2011-04-21 2018-09-28 洛克菲勒大学 用于革兰氏阳性菌检测和治疗的链球菌属细菌噬菌体溶素
EA201391456A1 (ru) 2011-05-17 2014-05-30 Глаксосмитклайн Байолоджикалс С.А. ВАКЦИНА ПРОТИВ Streptococcus pneumoniae
AU2012318609B2 (en) * 2011-10-05 2018-02-08 The Rockefeller University Dimeric bacteriophage lysins
JP2015510872A (ja) 2012-03-07 2015-04-13 ノバルティス アーゲー Ｓｔｒｅｐｔｏｃｏｃｃｕｓｐｎｅｕｍｏｎｉａｅ抗原の増強された製剤
CA2900008C (en) 2013-02-07 2025-10-07 Children's Medical Center Corporation PROTEIN ANTIGENS THAT CONFER PROTECTION AGAINST COLONIZATION AND/OR PNEUMOCOCCAL DISEASE
US9107906B1 (en) 2014-10-28 2015-08-18 Adma Biologics, Inc. Compositions and methods for the treatment of immunodeficiency
EP3220937B1 (en) 2014-11-21 2024-09-04 The Board of Regents of the University of Oklahoma Pneumolysin mutants and methods of use thereof
GB201610599D0 (en) * 2016-06-17 2016-08-03 Glaxosmithkline Biologicals Sa Immunogenic Composition
US11951165B2 (en) 2016-12-30 2024-04-09 Vaxcyte, Inc. Conjugated vaccine carrier proteins
EP4588521A3 (en) 2016-12-30 2025-10-22 Vaxcyte, Inc. Polypeptide-antigen conjugates with non-natural amino acids
US10259865B2 (en) 2017-03-15 2019-04-16 Adma Biologics, Inc. Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection
HRP20241185T1 (hr) 2017-09-07 2024-11-22 Merck Sharp & Dohme Llc Pneumokokni polisaharidi i njihova primjena u imunogenim konjugatima polisaharid-proteinski nosač
CA3111459A1 (en) 2018-09-12 2020-03-19 Affinivax, Inc. Multivalent pneumococcal vaccines
KR20240099160A (ko) 2021-09-09 2024-06-28 아피니백스, 인크. 다가 폐렴구균 백신

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MC2178A1 (fr) 1988-12-16 1992-05-22 Nederlanden Staat Mutants de la pneumolysine et vaccins a base de pneumocoque prepares a partir de ces mutants
EP0687688A1 (en) * 1993-12-17 1995-12-20 Universidad De Oviedo Antibodies against pneumolysine and their applications
US5565204A (en) * 1994-08-24 1996-10-15 American Cyanamid Company Pneumococcal polysaccharide-recombinant pneumolysin conjugate vaccines for immunization against pneumococcal infections
KR100619350B1 (ko) * 1997-07-21 2006-09-05 박스터 헬쓰케어 에스.에이. 변형 면역성 뉴멀리신 백신조성물
GB9717953D0 (en) * 1997-08-22 1997-10-29 Smithkline Beecham Biolog Vaccine
JP2002531055A (ja) * 1998-07-27 2002-09-24 マイクロビアル テクニクス リミティッド 肺炎連鎖球菌のタンパク質及び核酸分子
JP2002531135A (ja) * 1998-12-04 2002-09-24 ユニヴァーシティ オブ マニトーバ クラミジア感染に対する２段階免疫感作法
JP2002533124A (ja) * 1998-12-31 2002-10-08 カイロン コーポレイション Ｈｉｖポリペプチドの改善された発現およびウイルス様粒子の生成
CA2406678A1 (en) * 1999-12-17 2001-06-21 American Cyanamid Company Method of enhancing immune responses to herpes simplex virus vaccine

Also Published As

Publication number Publication date
AU2003291365B2 (en) 2009-06-11
US20080199952A1 (en) 2008-08-21
HK1074005A1 (en) 2005-10-28
EP1558280A4 (en) 2007-08-29
CN1711105A (zh) 2005-12-21
US20040213803A1 (en) 2004-10-28
AU2003291365A1 (en) 2004-06-03
TWI315986B (en) 2009-10-21
CA2504938A1 (en) 2004-05-27
US7217791B2 (en) 2007-05-15
ES2451620T3 (es) 2014-03-28
WO2004043376A3 (en) 2004-10-14
CN100443116C (zh) 2008-12-17
KR20050086427A (ko) 2005-08-30
JP2006506989A (ja) 2006-03-02
JP2010057501A (ja) 2010-03-18
TW200418502A (en) 2004-10-01
US7585669B2 (en) 2009-09-08
EP1558280B1 (en) 2014-01-08
JP2012139221A (ja) 2012-07-26
WO2004043376A2 (en) 2004-05-27
EP1558280A2 (en) 2005-08-03

Similar Documents

Publication Publication Date Title
US7585669B2 (en) Compositions and methods for treating or preventing pneumococcal infection
EP1648500B1 (en) Immunogenic compositions for streptococcus pyogenes
US7960535B2 (en) Recombinant lipidated PsaA protein, methods of preparation and use
CN101855238B (zh) 融合蛋白疫苗
EP2292645A2 (en) Small Streptococcus pyogenes antigens and their use
US6716432B1 (en) Pneumolysin mutants and pneumococcal vaccines made therefrom
KR20150034192A (ko) 폐렴 연쇄상구균에 의해 유발되는 폐렴에 대한 키메라 단백질 백신
AU2009323682A1 (en) Glutamyl tRNA synthetase (GtS) fragments
US20150079132A1 (en) Evoking protection against streptotoccus pneumoniae incorporating b-cell and t-cell pneumococcal protein antigens and pneumococcal polysaccharides delivered concomitantly
MX2014010011A (es) Proteinas y composiciones de pilus.
HK1074005B (en) Compositions and methods for treating or preventing pneumococcal infection
CA2488234A1 (en) Immunomodulatory constructs and their uses
AU2003204215B2 (en) Recombinant Lipidated PsaA Protein, Methods of Preparation and Use
Lee et al. Protective immunity and gene expression related to pneumococcal glycoconjugate
HK1250933A1 (en) Immunogenic fusion protein

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20231106